SonoCloud

Low Intensity Contact Ultrasound Implant 

The SonoCloud® Device

The SonoCloud® is an implantable medical device, which is fixed to the skull. Since the device must be MRI compatible, the device does not contain any integrated power source. The upper face, which is in contact with the underside of the skin, contains a connection channel that receives a bipolar needle which is introduced through the skin at each use. The bottom face, which is in contact with the dura mater and brain, consists of a transducer that emits ultrasound energy to open the blood-brain barrier.

The SonoCloud® device is powered and controlled by an external generator that verifies the quality of the electrical connection, delivers radio-frequency energy to power the device, and saves the entire procedure sequence.

Illustration of the top face of the SonoCloud®, which accepts a power source temporarily through a transcutaneous needle connection. The connection can be easily made by a nurse during each BBB opening procedure.

SonoCloud111

  • unnamed-2
    unnamed-3

     

  • News CarThera

    25.06.2019
    June 2019: CarThera appoints Pascal E. R. Girin as chairman of board of directors

    Pascal Girin brings wealth of experience in medical device and life sciences industries to support CarThera’s future growth. Girin has decades of business expertise in the life sciences and medical devices markets, most recently as CEO of Balt, a leader in the treatment of neurovascular diseases. Prior to this, he held numerous C-level positions at leading medical companies, including Wright Medical, Keystone Dental (a Warburg Pincus company), EV3, Baxter and Ohmeda, among others. As chairman of CarThera’s board of directors, he will bring invaluable insight to the company’s business strategy and future development.

    Read more
    25.06.2019
    March 19: CarThera publishes complete results of Phase I/IIa clinical trial using its SonoCloud-1 ultrasound implant

    Final results of the phase I/IIa clinical trial (NCT02253212) on the ultrasound-induced blood-brain barrier (BBB) opening improving the efficiency of carboplatin chemotherapy for recurrent glioblastoma patients were published in AACR’s Clinical Cancer Research journal of the . Study results show a good safety profile and encouraging efficacy. These results are based on 65 sonication sessions with escalating ultrasound pressure levels. GBM patients treated with optimal pressure levels and MRI-detected disrupted BBB (11 patients) showed a median progression-free survival (PFS) of 4.11 months and a median overall survival (OS) of 12.94 months. This compares to 2.73 months and 8.64 months respectively, for GBM patients without BBB disruption (8 patients).

    Read more
    13.12.2018
    CarThera closes €9M ($10.3M) Series B funding round

    €9M ($10.3M) was raised with three institutional investors, Panakès Partners, Sham Innovation Santé (advised by Turenne Capital) and Supernova Invest via its fund Supernova 2, as well as Group Arnault and historical investors. The proceeds will be used to further advance the SonoCloud technology and develop the clinical pipeline of the company. A multi-center study has already been launched in France and in the US to evaluate the SonoCloud-9 device, a new generation of implant with nine ultrasound emitters, in patients with recurrent glioblastoma. The company also has an on-going clinical study with the SonoCloud-1 device in patients with Alzheimer’s disease and one planned for patients with brain metastases.

    Read more
    All the news